The Global Celiac Disease Treatment Market was valued at USD 712.6 million in 2025 and is estimated to grow at a CAGR of 10.8% to reach USD 2 billion by 2035.
The celiac disease treatment industry is experiencing strong growth due to the rising prevalence of the condition and improved awareness among healthcare professionals regarding advanced diagnostic solutions. As detection rates increase, the demand for effective treatment options continues to rise, supporting overall market expansion. Ongoing research and development efforts are driving innovation in pharmaceutical therapies, contributing to a broader pipeline of potential treatments expected to enter the market. At the same time, the growing adoption of gluten-free dietary practices and advancements in non-invasive diagnostic methods are improving disease management and enabling quicker diagnosis. Expansion of specialized healthcare facilities focused on gastrointestinal disorders, along with better access to treatment services, is further strengthening patient adoption rates. Increasing investments in clinical trials targeting advanced therapeutic approaches, along with the availability of supportive care products for long-term management, are enhancing treatment adherence. Rising healthcare spending and improved distribution networks for medical nutrition and prescription therapies are also playing a key role in driving sustained growth across the market.
The vitamins and minerals supplements segment reached USD 345.4 million in 2025 and is projected to increase to USD 950.7 million by 2035. This segment holds a strong position due to the essential role of nutritional supplementation in managing deficiencies associated with the condition. Patients often rely on these supplements to support recovery and maintain overall health, particularly in addressing nutrient absorption challenges. Growing demand for specialized nutritional products tailored to individuals with dietary restrictions is further contributing to segment growth, as these solutions support digestive health and long-term disease management.
The oral segment accounted for 63.3% share in 2025 and is expected to grow at a CAGR of 10.7% throughout 2035. Oral therapies are widely preferred due to their convenience and ease of administration, allowing patients to manage treatment independently without requiring clinical assistance. Regulatory support for innovative oral formulations, combined with continuous research and development activities, is leading to the introduction of more effective and accessible treatment options, which are driving segment expansion.
North America Celiac Disease Treatment Market held a 44.2% share in 2025 and is anticipated to grow at a CAGR of 10.6% through 2035. The region’s growth is supported by a well-established healthcare infrastructure and a strong presence of pharmaceutical companies engaged in autoimmune disease research. High adoption of advanced therapies, favorable reimbursement policies, and increasing focus on clinical development for innovative treatments are further accelerating market expansion across the region.
Key companies operating in the Global Celiac Disease Treatment Market include Amgen, Takeda Pharmaceutical Company, ActoBio, Novartis, Teva Pharmaceutical, Viatris, Amneal Pharmaceuticals, BioLineRx, Calypso Biotech, Hikma Pharmaceuticals, Glenmark Life Sciences, Zydus Pharmaceuticals, Innovate Biopharmaceutical, and General Mills. Companies in the Celiac Disease Treatment Market are focusing on strengthening their market position through continuous innovation and strategic initiatives. Significant investments are being made in research and development to advance targeted therapies and improve treatment effectiveness. Organizations are actively pursuing collaborations, partnerships, and licensing agreements to accelerate product development and expand their therapeutic portfolios. Increasing focus on clinical trials is enabling the introduction of novel treatment options with improved efficacy and safety profiles. Companies are also enhancing their distribution networks and expanding into emerging markets to capture new growth opportunities.
This product will be delivered within 2-4 business days.
The celiac disease treatment industry is experiencing strong growth due to the rising prevalence of the condition and improved awareness among healthcare professionals regarding advanced diagnostic solutions. As detection rates increase, the demand for effective treatment options continues to rise, supporting overall market expansion. Ongoing research and development efforts are driving innovation in pharmaceutical therapies, contributing to a broader pipeline of potential treatments expected to enter the market. At the same time, the growing adoption of gluten-free dietary practices and advancements in non-invasive diagnostic methods are improving disease management and enabling quicker diagnosis. Expansion of specialized healthcare facilities focused on gastrointestinal disorders, along with better access to treatment services, is further strengthening patient adoption rates. Increasing investments in clinical trials targeting advanced therapeutic approaches, along with the availability of supportive care products for long-term management, are enhancing treatment adherence. Rising healthcare spending and improved distribution networks for medical nutrition and prescription therapies are also playing a key role in driving sustained growth across the market.
The vitamins and minerals supplements segment reached USD 345.4 million in 2025 and is projected to increase to USD 950.7 million by 2035. This segment holds a strong position due to the essential role of nutritional supplementation in managing deficiencies associated with the condition. Patients often rely on these supplements to support recovery and maintain overall health, particularly in addressing nutrient absorption challenges. Growing demand for specialized nutritional products tailored to individuals with dietary restrictions is further contributing to segment growth, as these solutions support digestive health and long-term disease management.
The oral segment accounted for 63.3% share in 2025 and is expected to grow at a CAGR of 10.7% throughout 2035. Oral therapies are widely preferred due to their convenience and ease of administration, allowing patients to manage treatment independently without requiring clinical assistance. Regulatory support for innovative oral formulations, combined with continuous research and development activities, is leading to the introduction of more effective and accessible treatment options, which are driving segment expansion.
North America Celiac Disease Treatment Market held a 44.2% share in 2025 and is anticipated to grow at a CAGR of 10.6% through 2035. The region’s growth is supported by a well-established healthcare infrastructure and a strong presence of pharmaceutical companies engaged in autoimmune disease research. High adoption of advanced therapies, favorable reimbursement policies, and increasing focus on clinical development for innovative treatments are further accelerating market expansion across the region.
Key companies operating in the Global Celiac Disease Treatment Market include Amgen, Takeda Pharmaceutical Company, ActoBio, Novartis, Teva Pharmaceutical, Viatris, Amneal Pharmaceuticals, BioLineRx, Calypso Biotech, Hikma Pharmaceuticals, Glenmark Life Sciences, Zydus Pharmaceuticals, Innovate Biopharmaceutical, and General Mills. Companies in the Celiac Disease Treatment Market are focusing on strengthening their market position through continuous innovation and strategic initiatives. Significant investments are being made in research and development to advance targeted therapies and improve treatment effectiveness. Organizations are actively pursuing collaborations, partnerships, and licensing agreements to accelerate product development and expand their therapeutic portfolios. Increasing focus on clinical trials is enabling the introduction of novel treatment options with improved efficacy and safety profiles. Companies are also enhancing their distribution networks and expanding into emerging markets to capture new growth opportunities.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Treatment, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Route of Administration, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this Celiac Disease Treatment market report include:- ActoBio
- Amgen
- Amneal Pharmaceuticals
- BioLineRx
- Calypso Biotech
- General Mills
- Glenmark Life Sciences
- Hikma Pharmaceuticals
- Innovate Biopharmaceutical
- Novartis
- Takeda Pharmaceutical Company
- Teva Pharmaceutical
- Viatris
- Zydus Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 131 |
| Published | April 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 712.6 Million |
| Forecasted Market Value ( USD | $ 2000 Million |
| Compound Annual Growth Rate | 10.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
